Incyte (INCY) EBITDA Margin (2009 - 2026)
Incyte's EBITDA Margin was -43.94% in Q3 2026, down 78.16 percentage points from 34.23% a year earlier and down 87.21 percentage points from the prior quarter.
Powered by 
Analysis
Incyte (INCY) EBITDA Margin (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Incyte's EBITDA Margin was 12.06% through Sep 30, 2026, down 20.61 percentage points year-over-year; for FY2025, it came in at 31.28%, up 27.73 percentage points from FY2024.
- EBITDA Margin shows a five-year change of +39.22 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was 3.55% in FY2024 (-15.48 pp), 19.03% in FY2023 (-0.04 pp), 19.07% in FY2022 (-2.48 pp) and 21.55% in FY2021 (+29.50 pp).
- The Q3 2026 figure marks the lowest quarterly EBITDA Margin since Q1 2020.
- Compared with a year earlier, EBITDA Margin was higher in five of the last eight quarters, with an average year-over-year change of +5.51 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was Q2 2025 (a gain of 89.21 percentage points); the worst was Q3 2026 (a drop of 78.16 percentage points).
- Per Business Quant data, INCY's EBITDA Margin in the three quarters before Q3 2026 was 43.27% (Q2 2026), 25.53% (Q1 2026) and 23.88% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Incyte | 245.42 Mn | -15.74 Bn | 1.45 Bn | -43.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -43.94% |
| Jun 30, 2026 | 43.27% |
| Mar 31, 2026 | 25.53% |
| Dec 31, 2025 | 23.88% |
| Sep 30, 2025 | 34.23% |
| Jun 30, 2025 | 45.51% |
| Mar 31, 2025 | 21.61% |
| Dec 31, 2024 | 27.51% |
| Sep 30, 2024 | 14.82% |
| Jun 30, 2024 | -43.70% |
| Mar 31, 2024 | 12.92% |
| Dec 31, 2023 | 20.63% |
| Sep 30, 2023 | 25.69% |
| Jun 30, 2023 | 22.43% |
| Mar 31, 2023 | 5.44% |
| Dec 31, 2022 | 9.53% |
| Sep 30, 2022 | 18.83% |
| Jun 30, 2022 | 29.73% |
| Mar 31, 2022 | 18.14% |
| Dec 31, 2021 | 14.56% |
API Access
Incyte EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INCY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "INCY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INCY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();